Valeant Pharmaceuticals International (VRX) Posts Q1 EPS of $0.02, Tops Revenue Expectations and Raises FY11 Guidance
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $0.02, versus ($0.02) reported last year. Revenue for the quarter came in at $565 million versus the consensus estimate of $297.08 million.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.